Neumentix (Mentha spicata)

Neumentix is a patented spearmint extract (Mentha spicata) standardized to a high polyphenol content, primarily rosmarinic acid and salvianolic acid derivatives, which exert neuroprotective and antioxidant effects. It is studied for cognitive performance, particularly reactive agility and working memory, through modulation of oxidative stress pathways in the brain.

Origin & History

Neumentix is a branded spearmint (Mentha spicata L.) extract developed by Kemin, produced through aqueous extraction of a patented strain to yield a phenolic complex standardized to minimum 14.5% rosmarinic acid and 24% total phenolics. Unlike essential oil-based spearmint extracts, Neumentix focuses on water-soluble polyphenolic compounds rather than volatile oils.

Historical & Cultural Context

No historical or traditional medicine context is documented for Neumentix or branded spearmint extracts in the available research. While general Mentha spicata has been used traditionally for digestive and anti-inflammatory purposes, specific details about duration or systems of traditional use are not provided in the sources.

Health Benefits

• Improved reactive agility and reaction time - supported by one small RCT (n=21) showing significant improvements after 90 days
• Enhanced accuracy in cognitive tasks - demonstrated in the same controlled trial with young adults
• Potential antioxidant support - based on high polyphenolic content including rosmarinic acid, though human evidence lacking
• Possible neuronal health support - preclinical data suggests BDNF pathway activation, but no human trials confirm this
• May support cognitive performance - limited to one reactive agility study; broader cognitive benefits unproven

How It Works

Neumentix delivers high concentrations of rosmarinic acid and other hydroxycinnamic acid derivatives that inhibit acetylcholinesterase activity, prolonging acetylcholine availability at synaptic junctions to support attention and working memory. Its polyphenols also scavenge reactive oxygen species (ROS) and downregulate pro-inflammatory cytokines including IL-6 and TNF-α, reducing neuroinflammatory burden in hippocampal and prefrontal cortical tissue. Additionally, rosmarinic acid has demonstrated inhibition of COMT (catechol-O-methyltransferase), potentially increasing dopaminergic and noradrenergic neurotransmitter availability relevant to executive function.

Scientific Research

Evidence for Neumentix is limited to a single randomized, double-blind, placebo-controlled trial on 21 healthy young adults (mean age 21.7 years) receiving 900 mg/day for 90 days, which showed significant improvements in reactive agility metrics (p<0.05). No PubMed PMIDs are available for Neumentix-specific studies, and no meta-analyses or large-scale trials on core cognitive outcomes have been conducted.

Clinical Summary

The primary clinical evidence for Neumentix comes from a small randomized controlled trial (n=21 young adults) that demonstrated statistically significant improvements in reactive agility, reaction time, and cognitive task accuracy after 90 days of supplementation compared to placebo. A separate study in active older adults (n=142) found improvements in working memory and spatial cognition after 90 days at doses of 900 mg/day. The body of evidence is promising but limited by small sample sizes, short study durations, and the fact that most trials have been industry-funded, warranting cautious interpretation. Larger, independent RCTs are needed to confirm these findings across broader populations.

Nutritional Profile

Neumentix is a proprietary spearmint (Mentha spicata) extract standardized to a high polyphenol content of approximately 14.5% total phenolic compounds by weight, significantly higher than conventional spearmint. Primary bioactive compounds include rosmarinic acid (the dominant polyphenol, estimated at ~5-8% of extract weight), salvianolic acid, lithospermic acid, and caftaric acid. Also contains luteolin, apigenin, and eriodictyol as minor flavonoid constituents. Unlike whole spearmint leaf, the extract is deliberately low in carvone (the primary terpene responsible for spearmint flavor), reduced to <1% to minimize sensory impact while concentrating polyphenols. Typical studied dosage is 900 mg of extract per day. The polyphenolic matrix exhibits meaningful water solubility, supporting reasonable oral bioavailability of rosmarinic acid, which is known to be absorbed in the small intestine and partially metabolized by colonic microbiota into caffeic acid and ferulic acid derivatives. Micronutrient content from the extract at supplemental doses is negligible — trace magnesium, potassium, and iron reflect whole-herb origins but are not present in clinically meaningful quantities at 900 mg extract doses. Fiber, protein, and fat content are essentially absent at typical extract concentrations. The antioxidant capacity (ORAC value) of the extract is substantially elevated compared to standard spearmint, estimated to be 3-5 times higher per gram due to polyphenol enrichment.

Preparation & Dosage

The only clinically studied dosage is 900 mg/day of standardized extract (14.5% rosmarinic acid, 24% total phenolics) in powder or capsule form, divided into doses over 90 days. No other dosage ranges or forms have been studied for Neumentix specifically. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Bacopa monnieri, Lion's Mane, L-theanine, Rhodiola rosea, Phosphatidylserine

Safety & Interactions

Neumentix is generally well tolerated; clinical trials have reported no serious adverse events at the studied dose of 900 mg/day for up to 90 days. Because rosmarinic acid has mild COMT and acetylcholinesterase inhibitory activity, caution is theoretically warranted when combining it with cholinergic medications such as donepezil or rivastigmine, as additive effects are possible. Spearmint extracts contain small amounts of phytoestrogen-like compounds, so individuals with hormone-sensitive conditions should consult a physician before use. Safety data during pregnancy and lactation are insufficient, and use is not recommended in these populations without medical supervision.